Fax: (212) 794-5851
Clinical benefits of a multivariate prediction model for bladder cancer†
A decision analytic approach
Article first published online: 12 OCT 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 23, pages 5460–5469, 1 December 2009
How to Cite
Vickers, A. J., Cronin, A. M., Kattan, M. W., Gonen, M., Scardino, P. T., Milowsky, M. I., Dalbagni, G., Bochner, B. H. and for The International Bladder Cancer Nomogram Consortium (2009), Clinical benefits of a multivariate prediction model for bladder cancer. Cancer, 115: 5460–5469. doi: 10.1002/cncr.24615
See editorial on pages 5368-70, this issue.
- Issue published online: 19 NOV 2009
- Article first published online: 12 OCT 2009
- Manuscript Accepted: 2 MAR 2009
- Manuscript Revised: 25 FEB 2009
- Manuscript Received: 14 NOV 2008
Vol. 117, Issue 16, 3867, Article first published online: 26 JAN 2011
- bladder cancer;
- adjuvant chemotherapy;
- decision support;
It has been demonstrated that multivariate prediction models predict cancer outcomes more accurately than cancer stage; however, the effects of these models on clinical management are unclear. The objective of the current study was to determine whether a previously published multivariate prediction model for bladder cancer (“bladder nomogram”) improved medical decision making when referral for adjuvant chemotherapy was used as a model.
Data were analyzed from an international cohort study of 4462 patients who underwent cystectomy without chemotherapy from 1969 to 2004. The number of patients eligible for chemotherapy was determined using pathologic stage criteria (lymph node-positive disease or pathologic T3 [pT3] or pT4 tumor classification) and for 3 cutoff levels on the bladder nomogram (10%, 25%, and 70% risk of recurrence with surgery alone). The number of recurrences was calculated by applying a relative risk reduction to the baseline risk among eligible patients. Clinical net benefit was then calculated by combining recurrences and treatments and weighting the latter by a factor related to drug tolerability.
A nomogram cutoff outperformed pathologic stage for chemotherapy in every scenario of drug effectiveness and tolerability. For a drug with a relative risk of 0.80, with which clinicians would treat ≤20 patients to prevent 1 recurrence, use of the nomogram was equivalent to a strategy that resulted in 60 fewer chemotherapy treatments per 1000 patients without any increase in recurrence rates.
The authors concluded that referring patients who undergo cystectomy to adjuvant chemotherapy on the basis of a multivariate model is likely to lead to better patient outcomes than the use of pathologic stage. Further research is warranted to evaluate the clinical effects of multivariate prediction models. Cancer 2009. © 2009 American Cancer Society.